Drug resistance to antibody-drug conjugates:mechanisms,challenges,and perspectivesOA
Drug resistance to antibody-drug conjugates:mechanisms,challenges,and perspectives
Yajing Liu;Yuwei Liu;Tingting Wu;Xiaoming Bai;Shuman Wang;Luyun Zhang;Zhiwen Fu;Chen Shi
Department of Pharmacy,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China||Hubei Province Clinical Research Center for Precision Medicine for Critical Illness,Wuhan 430022,ChinaDepartment of Pharmacy,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China||Hubei Province Clinical Research Center for Precision Medicine for Critical Illness,Wuhan 430022,ChinaDepartment of Pharmacy,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China||Hubei Province Clinical Research Center for Precision Medicine for Critical Illness,Wuhan 430022,ChinaDepartment of Pharmacy,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China||Hubei Province Clinical Research Center for Precision Medicine for Critical Illness,Wuhan 430022,ChinaDepartment of Pharmacy,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China||Hubei Province Clinical Research Center for Precision Medicine for Critical Illness,Wuhan 430022,ChinaDepartment of Pharmacy,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China||Hubei Province Clinical Research Center for Precision Medicine for Critical Illness,Wuhan 430022,ChinaDepartment of Pharmacy,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China||Hubei Province Clinical Research Center for Precision Medicine for Critical Illness,Wuhan 430022,ChinaDepartment of Pharmacy,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China||Hubei Province Clinical Research Center for Precision Medicine for Critical Illness,Wuhan 430022,China
Antibody-drug conjugatesdrug resistancecombination strategiescancer therapy
Antibody-drug conjugatesdrug resistancecombination strategiescancer therapy
《癌症生物学与医学（英文版）》 2026 (6)
833-864,32
This work was supported by the Joint Innovation Funding of the Natural Science Foundation of Hubei Province-Jiangsu-Hengrui Pharmaceuticals Company Ltd.(Grant No.2024AFD450)and the National Natural Science Foundation of China(Grant Nos.82073402 and 82204758).
评论